NCT00001173|Completed
Loading search results
Sponsor study identifier
Secondary identifiers
observational
200
1 country
1
Study Start
June 1980
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
June 2000
Date type not reportedThis date has not been verified as actual or estimated.
One of the major interests of this laboratory is the characterization of the cellular subpopulations involved in the triggering and immunoregulation of B lymphocytes to produce antibodies. We are assessing the responses of individuals to produce antibodies against newly encountered antigens such as keyhole limpet hemocyanin (KLH) (approved project number 77-I-0130) and propose to assess the amnestic responses to the previously encountered antigen, tetanus toxoid. The purpose of this protocol is to add this recall antigen to our repertoire of antigens used to evaluate the immune response in man. Booster immunization with tetanus/diphtheria toxoid has now been used for several years by a number of clinical immunology laboratories throughout the country to assess B cell related immunologic profiles in patients and control normal subjects. We have recently developed a sensitive ELISA assay for IgM and IgG in vitro specific antibody responses against tetanus toxoid. This will allow us to carefully and precisely monitor the evolution and immunoregulation of the human B cell responses to this recall antigen. This is of particular importance and relevance to us in our ongoing studies of a number of diseases characterized by abnormalities of immunologic reactivity, including those treated with various regimens of immunosuppressive agents.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 2000
Date type not reportedThis date has not been verified as actual or estimated.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 1980
Date type not reportedThis date has not been verified as actual or estimated.
November 3, 1999
Actual (reported)June 2000
Date type not reportedThis date has not been verified as actual or estimated.
December 10, 2002
Actual (reported)Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
National Institute of Allergy and Infectious Diseases (NIAID)
Bethesda, Maryland, 20892, United States
First Submitted
November 3, 1999
First Posted
December 10, 2002
Study Start
June 1980
Date type not reportedThis date has not been verified as actual or estimated.
Study Completion
June 2000
Date type not reportedThis date has not been verified as actual or estimated.
Phase I Trial of Smallpox Vaccine
Last Updated
March 4, 2008
Record last verified: 1999-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: